REMARKS

The Examiner has requested that the Applicant's provide a listing of all claims readable on the elected species. This listing is attached to this response as Appendix A.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant(s) petition(s) for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 549172000110.

Dated: August 25, 2003

Respectfully submitted,

By _____

Laurie L. Hill, Ph.D.
Registration No.: 51,804
MORRISON & FOERSTER LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130
(858) 720-5100

Appendix A

Listing of Claims Readable on the Elected Species:

37. (previously presented): A method of producing virally purged CD4+ cells, comprising:

(a) collecting mononuclear cells from a patient infected with HIV;

(b) contacting the cells with mitogenic antibodies to induce cell activation,

wherein, in the contacting step, the activation of the cells occurs under conditions that promote Th1 cell differentiation to produce a population of cells that contains predominantly Th1 cells;

(c) selecting CD4+ cells that are HIV- after activation; and

(d) inducing cell proliferation and expanding the selected cells to an excess of 1×10^{10} cells, wherein:

cell proliferation and expansion is performed in the absence of exogenous interleukin-2 (IL-2); and the cells are contained in a volume of a liter or less.

38. (previously presented): The method of claim 37, further comprising:

after selecting CD4+ cells that are HIV- and prior to expanding the selected cells, growing a plurality of aliquots in the presence of mitogenic agents;

selecting from the aliquots those that are HIV-; and

then expanding the selected cells to an excess of 1×10^{10} cells per liter.

154. (previously presented): The method of claim 40, wherein cell expansion is effected in a hollow fiber bioreactor.

160. (previously presented): The method of claim 37, wherein the cells are expanded to an excess of 10^{10} cells in a volume of 500 mls or less.

161. (previously presented): The method of claim 37, wherein the expansion of cells occurs under conditions that produce a cell density of greater than 10^8 cells/ml.

163. (previously presented): The method of claim 38, wherein the cells are expanded to an excess of 10^{10} cells in a volume of 500 mls or less.

164. (previously presented): The method of claim 38, wherein the expansion of cells occurs under conditions that produce a cell density of greater than 10^8 cells/ml.

165. (previously presented): The method of claim 37, wherein cell expansion is effected in a hollow fiber bioreactor.

166. (previously presented): The method of claim 38, wherein cell expansion is effected in a hollow fiber bioreactor.

167. (previously presented): The method of claim 39, wherein cell expansion is effected in a hollow fiber bioreactor.

170. (previously presented): The method of claim 37, wherein the conditions that promote Th1 cell differentiation to produce a population of cells that contains predominantly Th1 cells is selected from the group consisting of activation in the presence of gamma interferon, IL-12 and anti-IL-12 receptor antibodies.

174. (previously presented): The method of claim 37, wherein cells are activated by stimulation of the CD3 and CD28 cell surface antigens.

175. (previously presented): The method of claim 37, wherein cells are activated by contacting them with anti-CD3 and anti-CD28 antibodies.

177. (previously presented): The method of claim 37, further comprising re-infusing the virally purged cells into the patient.